Chimeric antigen receptors (CARs) from bench-to-bedside

Immunology Letters

Volumn 155, Issue 1-2, 2013, Pages 40-42

  Savoldo, Barbara ^a   Dotti, Gianpietro ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chimeric antigen receptor; Gene therapy; T cell immunotherapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; CANCER PATIENT; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE STORM; EX VIVO STUDY; GENE EXPRESSION; GENE TARGETING; HUMAN; LEUKEMIA; LYMPHOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUROBLASTOMA; PLASMID; PRIORITY JOURNAL; PROGENY; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT;

CHIMERIC ANTIGEN RECEPTOR; GENE THERAPY; T CELL IMMUNOTHERAPY;

ANIMALS; ANTIBODIES; CANCER VACCINES; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84887821385     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.09.014     Document Type: Review

References (40)

1. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993, 90:720-724.
2. Sadelain M., Brentjens R., Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013, 3:388-398.
3. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
4. Ramos C.A., Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011, 11:855-873.
5. Savoldo B., Ramos C.A., Liu E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011, 121:1822-1826.
6. Pule M.A., Savoldo B., Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
7. Kalos M., Levine B.L., Porter D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
8. Brentjens R.J., Davila M.L., Riviere I., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra38.
9. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
10. Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
11. Bonini C., Grez M., Traversari C., et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003, 9:367-369.
12. Bear A.S., Morgan R.A., Cornetta K., et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?. Mol Ther 2012, 20:246-249.
13. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
14. Singh H., Manuri P.R., Olivares S., et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008, 68:2961-2971.
15. Wilson M.H., Coates C.J., George A.L. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther 2007, 15:139-145.
16. Gattinoni L., Klebanoff C.A., Palmer D.C., et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005, 115:1616-1626.
17. Robbins P.F., Dudley M.E., Wunderlich J., et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004, 173:7125-7130.
18. Ma A., Koka R., Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006, 24:657-679.
19. Zehn D., King C., Bevan M.J., Palmer E. TCR signaling requirements for activating T cells and for generating memory. Cell Mol Life Sci 2012, 69:1565-1575.
20. Igney F.H., Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002, 71:907-920.
21. Maher J., Brentjens R.J., Gunset G., Riviere I., Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002, 20:70-75.
22. Vera J., Savoldo B., Vigouroux S., et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006, 108:3890-3897.
23. Imai C., Mihara K., Andreansky M., et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
24. Pule M.A., Straathof K.C., Dotti G., et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005, 12:933-941.
25. Rischer M., Pscherer S., Duwe S., et al. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol 2004, 126:583-592.
26. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
27. Berger C., Jensen M.C., Lansdorp P.M., et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008, 118:294-305.
28. Terakura S., Yamamoto T.N., Gardner R.A., et al. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 2012, 119:72-82.
29. Savoldo B., Rooney C.M., Di Stasi A., et al. Epstein-Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007, 110:2620-2630.
30. Rossig C., Bollard C.M., Nuchtern J.G., Rooney C.M., Brenner M.K. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002, 99:2009-2016.
31. Heczey A., Liu D., Courtney A.N., et al. NKT cells as a novel platform for cancer immunotherapy with chimeric antigen receptors. Mol Ther 2013, 21:S5. [abstract].
32. Cruz C.R., Micklethwaite K.P., Savoldo B., et al. Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study. Blood 2013, [Epub ahead of print].
33. Micklethwaite K.P., Savoldo B., Hanley P.J., et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010, 115:2695-2703.
34. Giordano Attianese G.M., Marin V., Hoyos V., et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood 2011, 117:4736-4745.
35. Hudecek M., Schmitt T.M., Baskar S., et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010, 116:4532-4541.
36. Lamers C.H., Sleijfer S., Vulto A.G., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006, 24:e20-e22.
37. Morgan R.A., Yang J.C., Kitano M., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
38. Straathof K.C., Pule M.A., Yotnda P., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005, 105:4247-4254.
39. Di Stasi A., Tey S.K., Dotti G., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.
40. Hoyos V., Savoldo B., Quintarelli C., et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24:1160-1170.